Listed on the Main Board of the Singapore Exchange in October 2005, C & O Pharmaceutical Technology (Holdings) Limited (“C&O”) is an established and integrated pharmaceutical group in China. Our business model spans the entire value chain in the pharmaceutical industry, from research and development, to manufacturing, as well as marketing and distribution of C&O branded and third party pharmaceutical products via an extensive distribution network covering all parts of China.

Our product portfolio comprises C&O branded products, imported products (to which we hold exclusive distribution rights) and third party products. Most of our own products are included in the National Health Insurance Scheme, focusing primarily on anti-infection and gastrointestinal drugs, drugs for ageing adults, as well as other specialised drugs.

With a strong emphasis on research and development, we continually expand the range of our C&O branded products with a deep pipeline of generic and patented drugs. At the same time, we relentlessly source for new pharmaceutical and healthcare products to be carried under our extensive distribution network in China.

With an integrated business model, we offer one-stop solutions to other pharmaceutical companies both in China and outside of China with our Contract Research (“CRO”) and Contract Manufacturing (“CMO”) services, as well as product registration and distribution services.